Theralase(R) Closes $1.1 M Non-Brokered Private Placement

Executive Summary

• Theralase® Technologies Inc. closed a non‑brokered private placement of 4,230,770 units at $0.26 CAD per unit, raising gross proceeds of $1,100,000 CAD.
• Each unit consists of one common share and one warrant to purchase an additional share at $0.36 CAD for five years.
• Proceeds will fund the Phase II NMIBC clinical study, working capital, and general corporate purposes.

Key Details

• Units Issued: 4,230,770 units total.
• Pricing: $0.26 CAD per unit; aggregate gross proceeds of $1,100,000 CAD.
• Unit Composition: 1 common share + 1 warrant (exercise price $0.36 CAD, exercisable for five years from closing).
• Use of Proceeds: Phase II non‑muscle invasive bladder cancer (NMIBC) clinical study, working capital, and general corporate purposes.
• Holding Period: Units subject to a four‑month‑plus‑one‑day hold period under Canadian securities laws, expiring July 11, 2026.
• Regulatory Conditions: Offering pending final acceptance from the TSX Venture Exchange.
• Related Party Transaction: 100,000 units (gross proceeds $26,000 CAD) issued to insiders; exempt from formal valuation and minority shareholder approval under MI 61‑101 due to size limits.
• Closing Timeline: Less than 21 days between filing of material change report and completion of the offering.

Notable Quotes

(No direct quotes were provided in the release.)